Corpus Intelligence IC Memo — BAYLOR ORTHOPEDIC AND SPINE HOSPITAL 2026-04-26 15:03 UTC
IC Memo — BAYLOR ORTHOPEDIC AND SPINE HOSPITAL
Investment Committee Memorandum | TX | 24 beds | Grade C | EBITDA uplift $9.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAYLOR ORTHOPEDIC AND SPINE HOSPITAL

CCN 670067 | TARRANT, TX | 24 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BAYLOR ORTHOPEDIC AND SPINE HOSPITAL is a 24-bed community hospital in TARRANT, TX with $133.8M in net patient revenue and a 39.8% operating margin. The hospital serves a payer mix of 45.9% Medicare, 0.0% Medicaid, and 54.1% commercial.

Thesis: Turnaround. Our ML models identify $9.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 39.8% to 47.2% (+736bps).

Net Revenue HCRIS$133.8M
Current EBITDA COMPUTED$53.3M
Operating Margin COMPUTED39.8%
Occupancy HCRIS25.2%
Revenue / Bed COMPUTED$5.6M
Net-to-Gross HCRIS34.7%
Distress Probability MLnan%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
246
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 39.8% places it above the state median. Among 246 size-comparable peers (12-48 beds), the median margin is -8.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-48), prioritizing same-state peers. 246 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAYLOR ORTHOPEDIC AND SPINE HO (Target)TX24$133.8M39.8%
WISE HEALTH SYSTEM - PARKWAYTX36$361.0M-15.5%
CORYELL MEMORIAL HOSPITALTX25$305.9M-1.5%
TEXAS ORTHOPEDIC HOSPITATX42$237.8M46.3%
METHODIST HOSPITAL FOR SURGERYTX32$178.4M22.8%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%
SCOTT AND WHITE HOSPITAL TAYLOTX25$139.7M-47.5%
BAYLOR SURGICAL HOSPITAL AT FOTX30$136.0M14.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $9.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.8M+210bp18mo
Cost to Collect4.5%2.5%$2.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.6M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.6M+122bp9mo
Clean Claim Rate88.0%96.0%$86K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.8M
Cost to Collect
$2.7M
Denial Rate Reduction
$2.6M
A/R Days Reduction
$1.6M
Clean Claim Rate
$86K
Total EBITDA Uplift$9.8M
Current EBITDA$53.3M
+ RCM Uplift+$9.8M
Pro Forma EBITDA$63.1M
Current Margin39.8%
Pro Forma Margin47.2%
WC Released (1x)$5.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$82.0M$450.0M5.49x40.6%
Base (11x exit)10.0x11.0x$82.0M$521.6M6.36x44.8%
Bull Case9.0x11.0x$73.8M$580.7M7.87x51.1%
Bull (12x exit)9.0x12.0x$73.8M$655.3M8.88x54.8%
Bear Case11.0x10.0x$90.2M$374.1M4.15x32.9%
Bear (11x exit)11.0x11.0x$90.2M$440.8M4.89x37.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 25.2%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 246 hospitals with 12-48 beds
  • Same-state prioritization (n=247)
  • Comp margins: P25=-37.8% / P50=-8.5% / P75=8.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.